Immunogen (IMGN) 10-Q2023 Q1 Quarterly report

Filed: 28 Apr 23, 4:02pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: adult, affirmative, alpha, announced, annum, anticancer, Arbuckle, Assay, authorisation, bank, began, BioPharma, BPCR, breast, broader, calendar, composition, confirmatory, create, created, customary, cycle, death, default, Department, Deposit, description, deteriorate, deterioration, disability, distributing, DOR, double, doubt, downturn, drawn, ELAHERE, EMA, enacted, environment, excluded, excluding, exposed, FDIC, feasible, Federal, field, floor, folate, Food, freight, Gilead, handling, headcount, infrastructure, instability, institution, jointly, loan, longer, low, LP, magrolimab, Master, mutual, National, NMPA, NSCLC, objective, obsolete, optimize, overnight, partner, Partnership, perfected, pharmacy, Pharmakon, prioritized, proceed, produced, producing, ratable, receivership, recoverability, regional, released, repay, request, reverse, RSU, RxDx, shipping, Signature, Silicon, single, SOFR, sound, specialty, standalone, stated, strategic, Stuart, succeed, systemic, team, tired, Tissue, tranche, unable, uncollectible, unpredictable, unstable, Valley, VENTANA, verification, Vertex, virtual

Removed: agreed, AgreementSM, authoritative, AVASTIN, bear, BLA, building, cease, chemistry, circumstance, close, computer, constrained, consultation, dated, dedicated, determining, distinct, Distinguishing, enrolling, equally, equipment, gain, goal, guidance, Gynecologic, Healthcare, Hedging, hold, IND, independent, investigational, judgment, maturity, median, minimum, MIRV, oncology, Open, pending, predominantly, professional, proximity, reach, redemption, remeasured, replace, represented, resolved, revert, settlement, SGO, soravtansine, SPA, stage, subsequently, uncertain, United, variable, Viridian

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated IMGN transcripts

IMGN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32

Certification

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of ImmunoGen, Inc., a Massachusetts corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The Quarterly Report for the period ended March 31, 2023 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: April 28, 2023	/s/ MARK J. ENYEDY
	Mark J. Enyedy
	President, Chief Executive Officer
	(Principal Executive Officer)

Dated: April 28, 2023	/s/ RENEE LENTINI
	Renee Lentini
	Vice President - Finance, Chief Accounting Officer, and Interim Chief Financial Officer
	(Principal Accounting Officer and Principal Financial Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.